Novo Nordisk Seeks FDA Approval of Higher Dose of Wegovy Weight-Loss Shot
Novo NordiskNovo Nordisk(US:NVO) WSJ·2025-11-26 13:42

Core Insights - The FDA is implementing a priority program to expedite the review of products that address significant health priorities [1] Group 1 - The program aims to accelerate the review process for health-related products [1]